VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference

Andrew Brenner

Medicine

Press/Media: Press / Media

Period	Sep 17 2015

Media coverage

29

Media coverage

Title	VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
Media name/outlet	Reuters
Country	United Kingdom
Date	9/17/15
Persons	Andrew Brenner

Title	VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
Media name/outlet	Yahoo! Finance
Country	United States
Date	9/17/15
Persons	Andrew Brenner

Title	VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
Media name/outlet	PharmiWeb
Country	United Kingdom
Date	9/17/15
Persons	Andrew Brenner

Title	VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
Media name/outlet	Town Hall
Country	United States
Date	9/17/15
Persons	Andrew Brenner

Title	VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
Media name/outlet	Vision Monday
Country	United States
Date	9/17/15
Persons	Andrew Brenner

Title	VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
Media name/outlet	Marketplace
Country	United States
Date	9/17/15
Persons	Andrew Brenner

Title	VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
Media name/outlet	Industrial Info Financials
Country	United States
Date	9/17/15
Persons	Andrew Brenner

Title	VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
Media name/outlet	CEOWorld Magazine
Country	United States
Date	9/17/15
Persons	Andrew Brenner

Title	VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
Media name/outlet	RCL Advisors
Country	United States
Date	9/17/15
Persons	Andrew Brenner

Title	VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
Media name/outlet	Wall Street Business Network
Country	United States
Date	9/17/15
Persons	Andrew Brenner

Title	VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
Media name/outlet	Crawford Financial Planning
Country	United States
Date	9/17/15
Persons	Andrew Brenner

Title	VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
Media name/outlet	Market Pulse Navigator
Country	United States
Date	9/17/15
Persons	Andrew Brenner

Title	VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
Media name/outlet	MoneyShow.com
Country	United States
Date	9/17/15
Persons	Andrew Brenner

Title	VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
Media name/outlet	Fat Pitch Financials
Country	United States
Date	9/17/15
Persons	Andrew Brenner

Title	VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
Media name/outlet	Reliance Trust
Country	United States
Date	9/17/15
Persons	Andrew Brenner

Title	VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
Media name/outlet	Franklin Credit Management Corporation
Country	United States
Date	9/17/15
Persons	Andrew Brenner

Title	VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
Media name/outlet	BioSpace
Country	United States
Date	9/17/15
Persons	Andrew Brenner

Title	VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
Media name/outlet	A.M. Best
Country	United States
Date	9/17/15
Persons	Andrew Brenner

Title	VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
Media name/outlet	SearchBug
Country	United States
Date	9/17/15
Persons	Andrew Brenner

Title	VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
Media name/outlet	Yahoo! 7 Finance
Country	Australia
Date	9/17/15
Persons	Andrew Brenner

Title	VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
Media name/outlet	4 Traders
Country	United States
Date	9/17/15
Persons	Andrew Brenner

Title	VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
Media name/outlet	Tamar Securities
Country	United States
Date	9/17/15
Persons	Andrew Brenner

Title	VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
Media name/outlet	Financial Content
Country	United States
Date	9/17/15
Persons	Andrew Brenner

Title	VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
Media name/outlet	Virtual Strategy Magazine
Country	United States
Date	9/17/15
Persons	Andrew Brenner

Title	VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
Media name/outlet	U-T San Diego
Country	United States
Date	9/17/15
Persons	Andrew Brenner

Title	VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
Media name/outlet	Good Day Sacramento
Country	United States
Date	9/17/15
Persons	Andrew Brenner

Title	VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
Media name/outlet	Ask.com
Country	United States
Date	9/17/15
Persons	Andrew Brenner

Title	VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
Media name/outlet	GlobeNewswire
Country	United States
Date	9/17/15
Persons	Andrew Brenner

Title	VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
Media name/outlet	BizWire Express
Country	India
Date	9/17/15
Persons	Andrew Brenner